Treatment update for autoimmune/immune-mediated central nervous system diseases
Autoimmune/immune-mediated central nervous system (CNS) diseases are chronic, inflammatory, autoimmune diseases, such as multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and autoimmune encephalitis (AE). A common pathological feature of these diseases is the targeting of the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2025-04-01
|
| Series: | Folia Neuropathologica |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Treatment-update-for-autoimmune-immune-mediated-central-nervous-system-diseases,20,55925,1,1.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850275627513413632 |
|---|---|
| author | Jiayi Wu Xuewei Li Jun Peng Wan Fu Shuangxi Chen Heng Wu |
| author_facet | Jiayi Wu Xuewei Li Jun Peng Wan Fu Shuangxi Chen Heng Wu |
| author_sort | Jiayi Wu |
| collection | DOAJ |
| description | Autoimmune/immune-mediated central nervous system (CNS) diseases are chronic, inflammatory, autoimmune diseases, such as multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and autoimmune encephalitis (AE). A common pathological feature of these diseases is the targeting of the host’s immune system against autoantigens expressed by the CNS. In recent years, immunomodulatory therapeutic drugs and methods with different targets have emerged. Therefore, obtaining a more comprehensive and in-depth understanding of the characteristics, adverse reactions and indications of existing therapeutic drugs is essential to develop individualized therapies based on each patient’s characteristics, delay the progression of disorders and enhance the life quality of these patients. Although MS, NMOSD, and AE are all associated with immune inflammation, there are considerable differences in clinical treatment. Certain drugs may be approved for only one of these diseases, while other drugs may be suitable for all three. This review systematically describes the characteristics and scope of application of various drugs, including potential drugs under development, as well as non-drug therapeutic approaches. |
| format | Article |
| id | doaj-art-8b2136e509bd44e8af52ffb9c9c4a9f2 |
| institution | OA Journals |
| issn | 1641-4640 1509-572X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Folia Neuropathologica |
| spelling | doaj-art-8b2136e509bd44e8af52ffb9c9c4a9f22025-08-20T01:50:39ZengTermedia Publishing HouseFolia Neuropathologica1641-46401509-572X2025-04-01631192910.5114/fn.2025.14947355925Treatment update for autoimmune/immune-mediated central nervous system diseasesJiayi WuXuewei LiJun PengWan FuShuangxi ChenHeng WuAutoimmune/immune-mediated central nervous system (CNS) diseases are chronic, inflammatory, autoimmune diseases, such as multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and autoimmune encephalitis (AE). A common pathological feature of these diseases is the targeting of the host’s immune system against autoantigens expressed by the CNS. In recent years, immunomodulatory therapeutic drugs and methods with different targets have emerged. Therefore, obtaining a more comprehensive and in-depth understanding of the characteristics, adverse reactions and indications of existing therapeutic drugs is essential to develop individualized therapies based on each patient’s characteristics, delay the progression of disorders and enhance the life quality of these patients. Although MS, NMOSD, and AE are all associated with immune inflammation, there are considerable differences in clinical treatment. Certain drugs may be approved for only one of these diseases, while other drugs may be suitable for all three. This review systematically describes the characteristics and scope of application of various drugs, including potential drugs under development, as well as non-drug therapeutic approaches.https://www.termedia.pl/Treatment-update-for-autoimmune-immune-mediated-central-nervous-system-diseases,20,55925,1,1.htmlmultiple sclerosis neuromyelitis optic spectrum disease autoimmune encephalitis |
| spellingShingle | Jiayi Wu Xuewei Li Jun Peng Wan Fu Shuangxi Chen Heng Wu Treatment update for autoimmune/immune-mediated central nervous system diseases Folia Neuropathologica multiple sclerosis neuromyelitis optic spectrum disease autoimmune encephalitis |
| title | Treatment update for autoimmune/immune-mediated central nervous system diseases |
| title_full | Treatment update for autoimmune/immune-mediated central nervous system diseases |
| title_fullStr | Treatment update for autoimmune/immune-mediated central nervous system diseases |
| title_full_unstemmed | Treatment update for autoimmune/immune-mediated central nervous system diseases |
| title_short | Treatment update for autoimmune/immune-mediated central nervous system diseases |
| title_sort | treatment update for autoimmune immune mediated central nervous system diseases |
| topic | multiple sclerosis neuromyelitis optic spectrum disease autoimmune encephalitis |
| url | https://www.termedia.pl/Treatment-update-for-autoimmune-immune-mediated-central-nervous-system-diseases,20,55925,1,1.html |
| work_keys_str_mv | AT jiayiwu treatmentupdateforautoimmuneimmunemediatedcentralnervoussystemdiseases AT xueweili treatmentupdateforautoimmuneimmunemediatedcentralnervoussystemdiseases AT junpeng treatmentupdateforautoimmuneimmunemediatedcentralnervoussystemdiseases AT wanfu treatmentupdateforautoimmuneimmunemediatedcentralnervoussystemdiseases AT shuangxichen treatmentupdateforautoimmuneimmunemediatedcentralnervoussystemdiseases AT hengwu treatmentupdateforautoimmuneimmunemediatedcentralnervoussystemdiseases |